Abstract
This study aims to develop novel azatyrosinamide compounds structurally modified from ras-specific antioncogenic azatyrosine. Analogues 4-15 were prepared and their inhibition on the growth of wild-type and ras-transformed NIH 3T3 cell lines was compared. Compound 12 was found to be the most active with IC50 16.5 ± 2.2 μM which is 458-fold more potent than that of azatyrosine. The selective toxicity, defined as IC 50 wild-type/IC50 ras-transformed for this compound was 138.5.
Original language | English |
---|---|
Pages (from-to) | 4272-4274 |
Number of pages | 3 |
Journal | Bioorganic and Medicinal Chemistry Letters |
Volume | 15 |
Issue number | 19 |
DOIs | |
State | Published - 01 10 2005 |